Overview of Firac Plus

Property	Description
Active ingredients	Clonixin, Pargeverine
Primary Form	Tablets, Capsules (Oral)
Pharmacological Class	Combination Analgesic and Antispasmodic Agent
General Purpose	Relief of pain associated with smooth muscle spasm
Origin	Synthetic

What Type of Medicine is Firac Plus?

Firac Plus is formally classified as a fixed-dose combination product, strategically uniting two distinct active substances, Clonixin and Pargeverine, to achieve a dual therapeutic action. This medicine is defined as a combination analgesic and antispasmodic agent, a pharmacological category clinically recognized for its utility in addressing complex visceral pain states. Firac Plus is typically presented in oral dosage forms, such as tablets or capsules, although parenteral preparations for injection may also be utilized. This combination type is distinctive because it provides a single-pill solution, streamlining the approach to managing pain and involuntary muscle contractions concurrently.

Composition: Clonixin, Pargeverine, and Dual Action

The medication’s active ingredients are Clonixin and Pargeverine, both synthetic components. Clonixin is the component that belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, primarily responsible for the drug’s pain-relieving and anti-inflammatory properties. Pargeverine functions as the antispasmodic agent, specifically targeting and relaxing the smooth muscle tissue of internal organs, a key function in treating visceral pain. The combination of these components ensures that the formulation simultaneously manages both the systemic inflammatory pain and the localized visceral cramping that characterizes many painful conditions.

Primary Therapeutic Purpose

The core therapeutic purpose of Firac Plus is to effectively interrupt the pain-spasm cycle by utilizing the synergy between its two active components. This combined mechanism delivers targeted pain reduction alongside smooth muscle relaxation, providing comprehensive relief from discomfort specifically associated with painful visceral cramping. The goal is the swift and reliable resolution of the painful episode stemming from both spasm and the accompanying inflammatory response.

What side effects are possible with Firac Plus?

Possible Side Effects and Safety Information

The safety profile for Firac Plus, as defined by governmental regulatory documents, includes specific warnings regarding serious adverse reactions and a defined set of more common side effects.

Serious and Clinically Significant Risks

Official regulatory information emphasizes an increased risk of several life-threatening events compared to certain other treatments for the same conditions. These serious adverse reactions include:

Serious Cardiovascular Events: Heart attack (myocardial infarction) and stroke.
Malignancy: An elevated risk of various cancers, including lymphoma and lung cancer.
Thrombosis: Increased risk of developing blood clots (e.g., deep vein thrombosis or pulmonary embolism).
Death: Increased overall mortality risk, with a higher rate observed across both tested doses.

Common Adverse Reactions

The frequency classifications for side effects are generally aligned with regulatory guidance (e.g., EMA/ICH frequency bands, where 'common' is 1/100 to < 1/10). The most common adverse reactions affect multiple system-organ classes, including:

Infections: Upper respiratory tract infections (e.g., common cold, sinusitis), bronchitis, shingles, and cold sores.
General: Headache and cough.
Gastrointestinal: Nausea and diarrhea.
Skin: Rash and acne.

Safety Monitoring

Regulatory documents highlight that the drug can lead to laboratory abnormalities, necessitating monitoring. These changes include increases in cholesterol and blood pressure levels, as well as elevated muscle enzyme levels (creatine phosphokinase). The presence of these documented serious risks requires careful evaluation of the drug's overall risk-benefit profile.

Adverse Reaction Category	Examples of Documented Reactions
Serious Risks	Heart attack, stroke, cancer (lymphoma, lung cancer), blood clots, death
Common Risks	Upper respiratory infections, bronchitis, headache, nausea, rash

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Firac Plus, which combines an analgesic and an antispasmodic, detail a specific overdose profile. Overdose manifestations may present with a dual pattern of toxicity involving the gastrointestinal system and the central nervous system (CNS). Documented clinical presentations include CNS effects such as confusion, agitation, disorientation, and drowsiness, alongside peripheral anticholinergic signs like mydriasis (dilated pupils) and tachycardia (increased heart rate). Gastrointestinal manifestations, including nausea, vomiting, and epigastric pain, are also reported.

When to Seek Help: It is explicitly stated that immediate medical attention must be sought for any suspected or confirmed overdose. Regulatory agencies mandate that emergency services be contacted without delay, particularly if severe CNS symptoms, respiratory compromise, or cardiovascular instability are present.

Severe Outcomes and Management: Serious or life-threatening outcomes documented in regulatory labeling include acute renal failure, severe gastrointestinal bleeding, convulsions, and progression to coma or circulatory collapse. Due to the lack of a specific reversal agent for the Clonixin component, management focuses on symptomatic and supportive treatment. This may involve procedures such as gastric lavage, administration of activated charcoal, and continuous hospital monitoring of renal and hepatic function. Regulatory information notes that overdose severity may be heightened in patients with pre-existing renal or hepatic impairment.

Therapeutic Uses of Firac Plus

What Firac Plus Treats: Main Uses and Benefits

Firac Plus is generally used to provide symptomatic relief for conditions marked by painful smooth muscle spasms, helping patients manage acute or recurrent episodes of discomfort. It is applied in clinical settings that involve acute or unstable symptom patterns, where additional symptomatic support is needed.

This medication is indicated for easing symptoms associated with conditions such as biliary colic, intestinal colic, renal colic, and spasmodic dysmenorrhea. It is relevant for easing symptom clusters that may become intense or disruptive in the abdominal, urinary, and reproductive systems.

Its use may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. It is applied in scenarios where short-term symptomatic assistance is required, supporting patients during difficult episodes.

Quick Fact: Supports Management of Spasmodic Visceral Pain

Regulatory References

DailyMed NIH Dicyclomine Hydrochloride Product Information

Eligibility and Restrictions for Use

Eligibility for Firac Plus: Official Regulatory Information

Firac Plus eligibility is governed by the combined mandatory restrictions for its two components, Clonixin (an NSAID) and Pargeverine (an anticholinergic spasmolytic).

Eligibility Status	Excluded Populations and Conditions
Absolute Contraindication	Known hypersensitivity to the drug or other NSAIDs; Active gastrointestinal ulceration, bleeding, or perforation; Severe Heart Failure (NYHA Class III-IV); Narrow-Angle Glaucoma; Third Trimester of Pregnancy (after 30 weeks gestation); pain management after CABG surgery (Coronary Artery Bypass Graft).
Use Not Recommended	Pediatric patients (under 18 years) due to safety and efficacy not being established; Breastfeeding individuals (an alternate drug is preferred); Moderate to Severe Renal or Hepatic Impairment.

Age and Physiological Rules

Use is generally permitted for adults (18 years and older) who do not have listed contraindications. However, older adults should use the medicine with caution due to a higher risk of adverse reactions tied to the NSAID component. Use is prohibited for infants and children as safety data is insufficient. These criteria strictly define who may and who must not use the medicine, as mandated by regulatory authorities.

What should I know about interactions with other medicines?

Firac Plus Interactions with other medicines and products

The official regulatory profile for Firac Plus is defined by the interaction properties of its two active components, Clonixin and Pargeverine. Co-administration constraints exist across several pharmacological classes, strictly based on pharmacodynamic and pharmacokinetic outcomes.

High-Risk and Restricted Combinations

The NSAID component, Clonixin, establishes high-risk restrictions. Co-administration with Anticoagulants, Antiplatelet Agents, or Thrombolytics is formally documented to increase the risk of bleeding and hemorrhage. Use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is restricted due to the potential for additive toxicity.

Pharmacokinetic and Pharmacodynamic Effects

Clonixin may interfere with the renal clearance of certain co-administered medicines that are primarily subject to renal excretion (e.g., Allopurinol, Acyclovir), which results in a decreased excretion rate and subsequent increased serum concentrations of those drugs. Pargeverine carries documented risks for additive effects: co-administration with other Anticholinergic Agents may amplify effects such as dry mouth or urinary retention. Furthermore, the combination may decrease the efficacy of Antihypertensive Agents.

Substance and Metabolic Interactions

Interaction with Alcohol is documented to exacerbate central nervous system effects, including drowsiness. Certain CYP450 Enzyme Inducers may accelerate the metabolism and clearance of the Pargeverine component, potentially leading to reduced effectiveness. No mandatory timing-based separation rules are currently documented in the official regulatory sources.

Mechanism of Action

Dual Inhibition of Prostaglandin Synthesis

The mechanism of Firac Plus centers on the inhibition of Cyclooxygenase (COX) enzymes. Aceclofenac functions as an inhibitor of COX-2 at sites of tissue perturbation, while Paracetamol influences COX activity primarily within the central nervous system. This enzyme inhibition blocks the synthesis of key molecular mediators, primarily Prostaglandin E2 ( PGE2), from the Arachidonic Acid Pathway. This action results in reduced sensitization of peripheral nociceptors and adjustment of the hypothalamic thermoregulatory set-point.

Central and Peripheral Nociceptive Pathway Modulation

This drug combination influences nociceptive signals at two distinct anatomical locations. Aceclofenac's peripheral action reduces the concentration of chemical mediators that promote nociception. In parallel, Paracetamol provides an influence through central nervous system (CNS) mechanisms, involving central COX inhibition and potential interaction with descending serotonergic systems. This dual targeting supports the modulation of nociceptive signaling, influencing the overall pattern of signal processing.

Dosage and Administration Information

How to Use Firac Plus

This section outlines the standardized administration of Firac Plus (Clonixin/Pargeverine combination) according to official prescribing information, focusing strictly on required use patterns.

Official Routes and Forms

Firac Plus is designated for administration via two principal routes. The primary route is Oral, utilizing the available tablet or capsule dosage forms for typical outpatient use. For rapid intervention in severe, acute painful episodes, a Parenteral (injectable) route may be employed in a supervised clinical setting.

Dosing and Frequency Schedule

Standard Unit Dose: The oral unit dose is one fixed-combination tablet, which typically contains 125 mg of Clonixin Lysine and 10 mg of Pargeverine Hydrochloride.

Dosing Frequency: The regimen is structured for multiple administrations per day to manage acute symptoms. Dosing is scheduled at intervals, often ranging from every 6 to 8 hours, with a strict limit to prevent exceeding the maximum daily dose specified on the specific product label.

Contextual and Duration Constraints

Timing Relative to Meals: The official instruction on whether to take the tablet with food or before meals is crucial and must be followed exactly as written on the product label. This specific timing balances the two components: the antispasmodic action and the gastrointestinal tolerance of the NSAID component.

Course Duration: Use is restricted to short-term symptomatic management of acute episodes. The total duration of therapy is typically limited to seven to ten days, and it is not intended for continuous, long-term use.

Population Adjustments: Official documentation requires consideration for dose adjustment in adult patients with pre-existing renal or hepatic impairment.

Recent Clinical Evidence

Firac Plus: Recent Clinical Evidence

Summary of Clinical Findings

Research has explored the evaluation of this combination in studies involving subjects with chronic conditions, particularly those experiencing pain and inflammation. Studies investigated the treatment in relation to changes in pain levels and time to onset of potential effect.

One area of investigation was the study of flare-up frequency among participants.

Furthermore, a randomized controlled trial (RCT) compared outcomes, including long-term functional changes, for participants using this regimen versus a standard treatment.

Pharmacokinetics and Dosing Study

Studies examined the pharmacokinetics of the treatment. Research also involved studying the mechanism of action. These investigations contribute to understanding how the agents are absorbed and distributed within the body.

Specific Population Data

The therapy's profile was studied in cohorts including older adults. Research also investigated the pharmacokinetics of varying doses in subjects with mild-to-moderate kidney impairment. This research helps define the drug’s profile across different patient groups.

The aggregated data was analyzed in relation to chronic joint pain outcomes. Additional research is ongoing to further evaluate the potential role of this treatment as a first-line option.

Key Studies & References Clinical Guideline for the Management of Chronic Musculoskeletal Pain (Focus on Combination Therapies)

Frequently Asked Questions (FAQ)

Common questions about Firac Plus (FAQ)

Q: How quickly does Firac Plus usually start working?

Official product information suggests that the base pain-relieving component, Clonixin, may begin to have an effect within 30 to 60 minutes after an oral dose. Individual results may vary based on a person’s metabolism and the nature of their symptoms.

Q: Can Firac Plus cause sleepiness or drowsiness?

Yes, official regulatory documents state that drowsiness and sedation are reported as potential adverse effects for the drug’s components. These central nervous system (CNS) effects are commonly associated with both the NSAID and the antispasmodic components.

Q: Can I take pain relievers (like ibuprofen or acetaminophen) with Firac Plus?

Regulatory documents strongly restrict taking Firac Plus with other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, due to the increased risk of additive toxicity. The official profile does not always clearly state interactions with non-NSAID pain relievers, such as acetaminophen (paracetamol). Information regarding all co-administered medicines is best clarified with a healthcare professional.

Q: Does alcohol make the side effects of Firac Plus worse?

Yes, official documents advise that consuming alcohol is documented to exacerbate certain central nervous system (CNS) effects, specifically increasing the risk of drowsiness and sedation. It is generally recommended to use caution regarding alcohol intake while taking this medicine.

Q: Does Firac Plus interact with birth control pills?

The official regulatory profile for this drug combination does not specifically list an interaction with hormonal contraceptives. However, some drugs in the NSAID class have been associated with potential interference. Always consult official patient labeling for the most comprehensive interaction information.

Q: Can a person stop taking Firac Plus suddenly?

As this is a short-term medication, regulatory information typically does not describe a required tapering schedule. However, stopping treatment suddenly is generally done after consultation with a healthcare professional to confirm that it is appropriate for the individual situation.

Q: Does taking Firac Plus at the same time every day matter?

Official regulatory documentation describes the dosing in terms of specific intervals (e.g., every 6 to 8 hours) with a maximum daily limit. Maintaining consistent spacing between doses is described as important to ensure effective symptom management and avoid exceeding the maximum dosage.

Q: Is it common for people to experience nausea when first starting Firac Plus?

Yes, nausea is listed in official documentation as a common adverse reaction that may be experienced by patients. Other common gastrointestinal effects include diarrhea.

Q: Can children or teenagers use Firac Plus?

Use is generally not recommended for pediatric patients, including children and teenagers (under 18 years). This is because regulatory authorities have determined that there is insufficient data to establish the medicine's safety and effectiveness in this younger population.

Q: Does the 'plus' ingredient change who can use the drug compared to the base drug?

Yes, the addition of the Pargeverine component introduces specific new contraindications that apply to the combination product. These restrictions include conditions such as Narrow-Angle Glaucoma, which may not apply if the patient was taking only the base NSAID component alone.

Q: Do I need a prescription to get Firac Plus?

Official regulatory classifications generally assign this type of fixed-dose combination analgesic and antispasmodic product as a prescription-only medicine (POM). It is intended for use under the supervision of a healthcare provider.

Q: Is there a risk of dependence associated with Firac Plus?

No, according to regulatory schedules, this medicine is not listed as a controlled substance. Official documents do not describe this product as having a risk of dependence or addiction.

Q: Why is grapefruit juice sometimes mentioned in drug warnings for medicines like this?

Warnings about grapefruit juice are common for drugs that are metabolized by specific liver enzymes (CYP450). Grapefruit can interfere with this process, potentially affecting the clearance of the Pargeverine component. This is a common warning for drugs that rely on these metabolic pathways.

Q: Is it mandatory to complete the full course of Firac Plus, even if I feel better?

Regulatory guidance strictly limits use to short-term symptomatic management (typically 7–10 days). While the duration of use is constrained, questions regarding continuing treatment after symptoms resolve are best directed to a healthcare professional.

Q: Can Firac Plus be crushed or chewed, or must it be swallowed whole?

Official instructions for the oral dosage form generally require the medicine to be swallowed whole without modification. Altering the tablet or capsule by crushing or chewing may affect how the fixed-dose combination product is absorbed by the body.

Q: Does Firac Plus have a Boxed Warning from regulatory agencies?

As the product contains an NSAID (Clonixin), it is subject to class-specific regulatory warnings. These can include warnings concerning serious adverse events related to the cardiovascular and gastrointestinal systems.

Q: Are there any major food interactions for Firac Plus?

Yes, the product label contains a specific instruction on whether the tablet should be taken with food or before meals. This timing is designed to balance the antispasmodic effect with the gastrointestinal tolerance of the NSAID component.

Q: Can Firac Plus cause changes in appetite or weight?

Changes in weight or appetite have been reported as adverse reactions for drugs that belong to the same pharmacological class as the components of Firac Plus. These are generally considered less common than other reported side effects.

Q: Is there a maximum time limit for using Firac Plus?

Yes. Official product information strictly restricts the use of Firac Plus to short-term symptomatic management only. The maximum duration of therapy is typically limited to a total of seven to ten days, and it is not intended for continuous, long-term use.

Q: Do any official documents describe Firac Plus as having an addictive potential?

No, official regulatory documents do not describe this medicine as having an addictive potential. Furthermore, it is not listed in regulatory schedules as a controlled substance.

Q: Does Firac Plus affect fertility in men or women?

The NSAID component (Clonixin) is described in some regulatory texts as potentially causing reversible effects on female fertility. Information regarding potential effects is a topic for discussion with a healthcare professional.

Q: Why is checking liver function sometimes required before starting a drug like Firac Plus?

Official documentation requires consideration for dose adjustment in adult patients with pre-existing hepatic (liver) impairment. This means that laboratory monitoring of liver function is often relevant for safe management of the medicine.

Q: Do official patient leaflets describe any long-term effects of using Firac Plus?

Because the drug is restricted by regulatory authorities to short-term symptomatic management (typically 7–10 days), official patient profiles do not typically include safety data or descriptions of effects for use beyond that duration.

Q: How long does Firac Plus typically stay in your system?

Research and official documents examined the pharmacokinetics of the treatment, which includes data on its half-life and rate of clearance from the body. These details describe how long the medicine takes to be eliminated.

Q: Is it safe to drive or operate machinery after taking Firac Plus?

Official warnings caution patients about engaging in activities like driving or operating machinery, as the drug can cause side effects such as drowsiness and dizziness that may affect performance.

Q: Is Firac Plus safe to use while breastfeeding?

Use of this medication is generally not recommended while breastfeeding, especially when nursing a newborn or preterm infant. Regulatory bodies usually suggest that an alternate drug is preferred in this situation.

How should Firac Plus be stored and disposed of?

How to Store and Dispose of Firac Plus

Official regulatory information specifies strict conditions for storing Firac Plus tablets to maintain stability.

Storage Requirements

The medication must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). Storage must always be in the original container, which must be kept tightly closed to provide necessary protection. It is mandatory to protect the tablets from light and excessive moisture. Do not freeze the product, and avoid exposure to high heat. As a universal requirement for all medicines, Firac Plus must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Firac Plus must be disposed of according to official regulatory guidelines. The preferred method is to utilize a community drug take-back program. If a take-back program is unavailable, the medicine should be disposed of by mixing it with an unappealing substance, sealing it in a bag, and placing it in the household trash. Do not flush the product down the toilet or pour it down a sink.

Firac Plus